Axoft Secures $55M in Series A Funding to Advance Soft Neural Interface Technology

Axoft just pulled $55M into a Series A, and somewhere between Cambridge lab benches and operating rooms in Panama, the future of brain tech got a little less theoretical and a lot more tactile. C.P. Group Innovation led the round, with Alumni Ventures doubling down alongside Stanford President’s Venture Fund, Hillhouse Investment, and Gaorong Ventures. Not bad company when you’re wiring up conversations between biology and silicon.

At the center of it, Dr. Paul Le Floch (CEO), Dr. Tianyang Ye (CTO), and Professor Jia Liu aren’t chasing noise. They’re engineering signal. This started in a Harvard lab where the idea was simple but brutal to execute. If the brain is soft, why are we still jamming rigid hardware into it and expecting clean data back? Axoft answered that question with Fleuron, a material that doesn’t just sit in the brain, it blends in. When your implant is up to 1,000,000x softer than silicon, you’re no longer forcing communication, you’re enabling it.

And the brain, when it’s comfortable, talks. 11 patients into first-in-human trials, real procedures, real stakes. Cortical mapping during tumor resections. Signals pulled from depths most devices can’t reach. 20 minutes of stable, single-neuron resolution data without drift. In a space where noise usually wins, Axoft is starting to isolate the signal with surgical precision.

The $55M isn’t just capital, it’s momentum with direction. Clinical trials scaling globally, FDA pathways tightening into focus, and a GMP facility taking shape near Boston’s innovation corridor. This isn’t a single product story. It’s a layered system play, where materials science feeds hardware, hardware feeds data, and data feeds intelligence. Quietly, they’re positioning themselves where neurotech meets AI, and that intersection tends to get very loud, very fast.

There’s a pattern here for anyone building in deep tech. The seed round in 2022 was $8M, led by The Engine, backing something most people couldn’t fully see yet. Fast forward 2.5 years, and Axoft is already inside the human brain with published validation and expanding clinical reach. That kind of velocity doesn’t come from hype. It comes from building something the real world can’t argue with.

Now the tone shifts. Because when the interface disappears and the data sharpens, the question isn’t whether we can read the brain. It’s what happens when we finally understand it well enough to respond in kind.